Loading
JW (Cayman) Therapeutics Co. Ltd - B Stock: price and insider trades · Hong Kong
1 insider bought €30k of shares over the last 90 days, the latest by TIAN FENG, filed 28 Jul 2026.
JW (Cayman) Therapeutics Co. Ltd - B: what insiders have been doing
This page follows insider dealings at JW (Cayman) Therapeutics Co. Ltd - B as filed with HKEX, a company from the Health Care sector. Between 24 October 2025 and 24 October 2026, 2 insiders published 7 filings.
Only purchases show up on the open market, 6 purchases in all worth €30k, filed by 1 insider. The amount is not disclosed for 2 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Tian Feng filed the largest purchase, €8,826, on 28 July 2026, which represents 0.012% of the company's market value. The buyers include 1 senior executive.
The last insider purchase was made public on 28 July 2026, 89 days ago. Filings reach the HKEX feed a median of 6 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done.
For context, the typical company on the same exchange (median of 1,315 companies) published 4 filings over the same period, against 7 filings here. The full history, which starts in 2021, counts 9 purchases against 5 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Insider Decl.
24
Thresholds
n/a
Buy Volume
€29,836
9 ops. · all time
Sell Volume
€2M
5 ops. · all time
Who traded when
BuySaleTian Feng6 buys
Liu Min1 buy
Since the insiders bought
- +0.0%Entry HK$0.20 · Close at T+30 HK$0.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,923 of 26,315 companies
28.0
score / 100
Value12
Quality44
FCF yld-7.9%
Earn yld-56%
EV/EBITDA·
ROE-50%
Gross mgn61%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$2.73
Analyst consensus
Income statement
RevenueHK$283.7M
Gross profitHK$173.1M61% margin
EBITDA-HK$458.9M-162% margin
Net income-HK$555.3M-117.3% margin
Valuation
P/Book2.1x
Beta1.79
Balance sheet & cash
Market capHK$1.1B
Total debtHK$262.6M
Free Cash Flow-HK$78.5M
Debt / Equity56%
Profitability & ownership
ROE-49.7%
ROA-12.4%
% insiders23.8%
% institutions0.3%
Last declaration on 28 July 2026
Declarations24 total
44,000 shares@ HK$1.7250.011% mcap28.4% of flowShareXHKGHKEX:DA20260728E00308
Canonical exit: 20 Oct 2026 (T+90)
25,000 shares@ HK$1.70460.0064% mcap15.9% of flowShareXHKGHKEX:DA20260728E00307
Canonical exit: 15 Oct 2026 (T+90)
37,500 shares@ HK$1.86410.010% mcap26.1% of flowShareXHKGHKEX:DA20260728E00306
Canonical exit: 14 Oct 2026 (T+90)
44,000 shares@ HK$1.800.012% mcap29.6% of flowShareXHKGHKEX:DA20260728E00305
Canonical exit: 8 Oct 2026 (T+90)
2,000,000 sharesShareXHKGHKEX:DA20260522E00020
Canonical exit: 17 Aug 2026 (T+90)
1,900,000 sharesShareXHKGHKEX:DA20260120E00034
Canonical exit: 16 Apr 2026 (T+90)
4,156,183 sharesShareXHKGHKEX:DA20251217E00437
556,935 sharesShareXHKGHKEX:DA20250710E00188
2,256,183 sharesShareXHKGHKEX:DA20250415E00354
Canonical exit: 10 Jul 2025 (T+90)
1,900,000 sharesShareXHKGHKEX:DA20240910E00194
Canonical exit: 1 Dec 2024 (T+90)
6,809,928 sharesShareXHKGHKEX:DA20230612E00359
1,221,291 sharesShareXHKGHKEX:DA20230130E00404
410,500 sharesShareXHKGHKEX:DA20230129E00002
369,000 sharesShareXHKGHKEX:DA20230129E00001
246,500 shares@ HK$5.72218.7% of flowShareXHKGHKEX:DA20230123E00028
346,500 shares@ HK$5.636712.1% of flowShareXHKGHKEX:DA20230123E00027
1,757,468 sharesShareXHKGHKEX:DA20221229E00398
5,588,637 sharesShareXHKGHKEX:DA20220414E00525
3,090,956 sharesShareXHKGHKEX:DA20220406E00158
4,242,532 sharesShareXHKGHKEX:DA20220331E00439
1,000,000 shares@ HK$13.303579.2% of flowShareXHKGHKEX:DA20211119E00027
6,034,895 sharesShareXHKGHKEX:DA20211012E00298
Canonical exit: 29 Dec 2021 (T+90)
4,699,530 sharesShareXHKGHKEX:DA20210428E00316
3,779,540 sharesShareXHKGHKEX:DA20210210E00167
24 of 24 declarations
About JW (Cayman) Therapeutics Co. Ltd - B
JW (Cayman) Therapeutics Co. Ltd - B is a company focused on developing innovative therapies. It concentrates on treatments for serious diseases and unmet medical conditions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
